HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price fell 3.2% on Friday . The company traded as low as $2.98 and last traded at $2.98. 100 shares changed hands during trading, a decline of 89% from the average daily volume of 904 shares. The stock had previously closed at $3.08.
HLS Therapeutics Trading Down 3.2%
The firm has a fifty day moving average price of $3.11 and a 200-day moving average price of $3.24.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
See Also
- Five stocks we like better than HLS Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
